Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Randomized Study to Evaluate the Safety, Efficacy, and Optimal Dose of Telisotuzumab Adizutecan in Combination With Fluorouracil, Leucovorin, and Budigalimab as First-Line Treatment in Subjects With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (AndroMETa-GEA-977)

NCT06628310 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT06628310
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06628310 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Randomized Study to Evaluate the Safety, Efficacy, and Optimal Dose of Telisotuzumab Adizutecan in Combination With Fluorouracil, Leucovorin, and Budigalimab as First-Line Treatment in Subjects With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (AndroMETa-GEA-977)
Lead sponsor
AbbVie
Phase
Phase 2
Overall status
Active, not recruiting
Start date
December 13, 2024
Completion date
October 31, 2030
Enrollment
185 (actual)
Sites
49

Conditions

As the registry lists them; a condition with its own page is linked.

esophageal adenocarcinoma, gastroesophageal junction adenocarcinoma, locally advanced unresectable or metastatic gastric adenocarcinoma